Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Faza IIB, randomizowane, podwójnie ślepe, kontrolowane placebo badanie ELISMETREP (K-304) w leczeniu migreny

25 września 2026 zaktualizowane przez: TriGemX Bio, Inc.

Faza IIB, randomizowane, podwójnie zaślepione, kontrolowane placebo badanie ELISMETREP (K-304) w leczeniu migreny: zostanie oceniony zakres dawek

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.

Przegląd badań

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

431

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Alabama
      • Birmingham, Alabama, Stany Zjednoczone, 35205
        • Central Research Associates, LLC (CRA) dba Flourish Research
      • Mobile, Alabama, Stany Zjednoczone, 36608
        • AMR Mobile
    • Arizona
      • Tucson, Arizona, Stany Zjednoczone, 85710
        • Wake Research/ Tucson Neuroscience Research
    • California
      • Canoga Park, California, Stany Zjednoczone, 91303
        • Hope Clinical Research
      • Encino, California, Stany Zjednoczone, 91316
        • WR-PRI, LLC (Encino)
      • Huntington Beach, California, Stany Zjednoczone, 92647
        • Marvel Clinical Research
      • La Mesa, California, Stany Zjednoczone, 91942
        • Eximia Research - CA
      • Lemon Grove, California, Stany Zjednoczone, 91945
        • Synergy San Diego
      • Newport Beach, California, Stany Zjednoczone, 92660
        • WR-PRI, LLC (Newport Beach)
      • Oceanside, California, Stany Zjednoczone, 92056
        • Excell Research, Inc.
      • Pomona, California, Stany Zjednoczone, 91767
        • Empire Clinical Research
      • Riverside, California, Stany Zjednoczone, 92503
        • Artemis Institute for Clinical Research - Riverside
      • San Diego, California, Stany Zjednoczone, 89109
        • Acclaim Clinical Research
      • San Diego, California, Stany Zjednoczone, 92103
        • Artemis Institute for Clinical Research - San Diego
      • Walnut Creek, California, Stany Zjednoczone, 94598
        • Diablo Clinical Research, Inc.
      • West Hills, California, Stany Zjednoczone, 91307
        • Focus Clinical Research
    • Connecticut
      • Cromwell, Connecticut, Stany Zjednoczone, 06416
        • CT Clinical Research
    • Georgia
      • Atlanta, Georgia, Stany Zjednoczone, 30329
        • DelRicht Research
      • Stockbridge, Georgia, Stany Zjednoczone, 30281
        • Clinical Research Atlanta - Stockbridge
    • Idaho
      • Boise, Idaho, Stany Zjednoczone, 83704
        • Northwest Clinical Trials
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60607
        • Cedar Crosse Research Center
      • Flossmoor, Illinois, Stany Zjednoczone, 60422
        • Healthcare Research Network II, LLC
    • Kansas
      • Overland Park, Kansas, Stany Zjednoczone, 66202
        • Collective Medical Research
      • Wichita, Kansas, Stany Zjednoczone, 67207
        • Alliance for Multispecialty Research
    • Kentucky
      • Louisville, Kentucky, Stany Zjednoczone, 40213
        • L-MARC Research Center
    • Louisiana
      • Chalmette, Louisiana, Stany Zjednoczone, 70043
        • Crescent City Headache & Neurology Center
      • New Orleans, Louisiana, Stany Zjednoczone, 70115
        • DelRicht Research
    • Michigan
      • Ann Arbor, Michigan, Stany Zjednoczone, 48104
        • Michigan Head Pain and Neurological Institute
    • Minnesota
      • Minneapolis, Minnesota, Stany Zjednoczone, 55402
        • Clinical Research Institute
    • Mississippi
      • Gulfport, Mississippi, Stany Zjednoczone, 39503
        • DelRicht Research
    • Missouri
      • Hazelwood, Missouri, Stany Zjednoczone, 63042
        • Healthcare Research Network
    • Nevada
      • Las Vegas, Nevada, Stany Zjednoczone, 89109
        • Excel Clinical Research
      • North Las Vegas, Nevada, Stany Zjednoczone, 89119
        • Las Vegas Clinical Trials
    • New Mexico
      • Albuquerque, New Mexico, Stany Zjednoczone, 87102
        • Albuquerque Clinical Trials, Inc.
    • New York
      • Amherst, New York, Stany Zjednoczone, 14226
        • Dent Neurosciences Research Center
      • Manlius, New York, Stany Zjednoczone, 13104
        • CNY Clinical Research
      • Rochester, New York, Stany Zjednoczone, 14609
        • Rochester Clinical Research
      • Williamsville, New York, Stany Zjednoczone, 14221
        • Upstate Clinical Research Associates LLC
    • North Carolina
      • Greensboro, North Carolina, Stany Zjednoczone, 27405
        • Headache Wellness Center
      • High Point, North Carolina, Stany Zjednoczone, 27260
        • Peters Medical Research
    • Ohio
      • Cincinnati, Ohio, Stany Zjednoczone, 45212
        • CTI Clinical Research Center
    • Oklahoma
      • Edmond, Oklahoma, Stany Zjednoczone, 73034
        • OK Clinical Research, LLC
      • Oklahoma City, Oklahoma, Stany Zjednoczone, 73102
        • Hightower Clinical
      • Tulsa, Oklahoma, Stany Zjednoczone, 74133
        • DelRicht Research
      • Yukon, Oklahoma, Stany Zjednoczone, 73099
        • Tekton Research
    • Oregon
      • Portland, Oregon, Stany Zjednoczone, 97210
        • Summit Research Network
    • Pennsylvania
      • Allentown, Pennsylvania, Stany Zjednoczone, 18103
        • Lehigh Center for Clinical Research
      • Philadelphia, Pennsylvania, Stany Zjednoczone, 19114
        • Clinical Research Philadelphia, LLC
      • Scottdale, Pennsylvania, Stany Zjednoczone, 15683
        • Frontier Clinical Research, LLC
      • Smithfield, Pennsylvania, Stany Zjednoczone, 15478
        • Frontier Clinical Research, LLC
      • West Chester, Pennsylvania, Stany Zjednoczone, 19380
        • Atlas-Clinical
    • South Carolina
      • Charleston, South Carolina, Stany Zjednoczone, 29406
        • Clinical Trials of South Carolina
      • North Charleston, South Carolina, Stany Zjednoczone, 29405
        • Coastal Carolina Research Center
    • Tennessee
      • Chattanooga, Tennessee, Stany Zjednoczone, 37421
        • WR-ClinSearch
      • Knoxville, Tennessee, Stany Zjednoczone, 37909
        • AMR Knoxville (Formerly NOCCR)
      • Nashville, Tennessee, Stany Zjednoczone, 37203
        • Clinical Research Associates, Inc.
    • Texas
      • Austin, Texas, Stany Zjednoczone, 78745
        • Tekton Research
      • Austin, Texas, Stany Zjednoczone, 78737
        • Donald J Garcia Jr, MD, PA
      • Dallas, Texas, Stany Zjednoczone, 75251
        • FutureSearch Trials of Dallas, LP
      • Houston, Texas, Stany Zjednoczone, 77024
        • Victorium Clinical Research LTD CO
      • Splendora, Texas, Stany Zjednoczone, 77372
        • APD Clinical Research
      • Waxahachie, Texas, Stany Zjednoczone, 75165
        • ClinPoint Trials
    • Utah
      • Ogden, Utah, Stany Zjednoczone, 84405
        • Advanced Research Institute
    • Virginia
      • Newport News, Virginia, Stany Zjednoczone, 23606
        • Health Research of Hampton Roads, Inc.
    • West Virginia
      • Morgantown, West Virginia, Stany Zjednoczone, 26505
        • Frontier Clinical Research, LLC
    • Wisconsin
      • Kenosha, Wisconsin, Stany Zjednoczone, 53144
        • Clinical Investigation Specialist

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 70 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Be a male or female, age 18 to 70 years, inclusive, at the time of signing informed consent.

  2. Participant has greater than a one-year history of migraine with or without aura as defined by International Conference on Harmonization (IHS) criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated as documented in the participant's medical records from his/her treating physician and confirmed by the investigator.

  3. Participant has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the two months prior to screening (Visit 1).

  4. Meet the following requirements:

    1. Is a male OR

    2. Is a female who is of non-childbearing potential defined by at least 1 of the following criteria:

    3. Postmenopausal (aged >45 years and with a minimum of 12 months of spontaneous amenorrhea with a screening serum follicle-stimulating hormone (FSH) level in the menopausal range established for the central laboratory.

    4. Post hysterectomy, bilateral oophorectomy or bilateral salpingectomy, based on the participant's recall of their medical history.

      OR

    5. Is a female of reproductive potential and:

    6. agrees to remain abstinent from heterosexual activity*

      *Abstinence can be used as the sole method of contraception if it is in line with the participant's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.

    7. or agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the end of trial (EoT) visit. Acceptable methods of birth control are:

      • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

        • oral
        • intravaginal
        • transdermal
      • progestogen-only hormonal contraception associated with inhibition of ovulation:

        • oral
        • injectable
        • implantable
      • intrauterine device (IUD)

      • intrauterine hormone-releasing system (IUS)

      • bilateral tubal occlusion

      • vasectomised partner

      • sexual abstinence

      • progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action

      • male or female condom with or without spermicide

      • cap, diaphragm or sponge with spermicide

      • A combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods)

    This condition is waived if the participant is proven to have no child-bearing potential (eg, hysterectomy).

  5. Participant voluntarily agrees to participate in the study by giving written informed consent.

  6. Participant is able to read, understand and complete the study questionnaires and diary.

  7. Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions.

  8. Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study.

Exclusion Criteria:

  1. Is a female who is pregnant, breast-feeding or intends to become pregnant during the planned course of the study. Note: Participants must have a negative serum pregnancy test (β-human chorionic gonadotropin (β-hCG)) performed by the central laboratory prior to enrollment in the study and negative urine pregnancy result at the randomization visit.

    Migraine history related

  2. Participant has difficulty distinguishing his/her migraine attacks from tension-type headaches.

  3. Participant has a history of predominantly mild migraine attacks or migraines that usually resolve spontaneously in less than two hours.

  4. Participant has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in any of the three months prior to screening (Visit 1).

  5. Participant has brainstem (a.k.a. basilar-type) or hemiplegic migraine headache, or retinal migraine.

  6. Participant was >50 years old at age of first migraine onset.

  7. Participant is taking migraine prophylactic medication where the prescribed daily dose has changed during the 3 months prior to screening (Visit 1) or anticipates any change during the study. Any withdrawal of preventive medications for the treatment of migraine should be completed at least 30 days prior to screening.

    Medical history related

  8. Participant has, in the opinion of the investigator, other confounding pain syndromes, psychiatric conditions such as uncontrolled major depression, history of psychosis, dementia or significant neurological disorders other than migraine [participants who are currently being treated with non-prohibited medication for depression and symptoms are well controlled, in the opinion of the investigator, are eligible to participate in this study].

  9. Participant is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator. Participants must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in the past 2 months or suicidal behavior in the past 6 months.

  10. Has a recent history (within the past 3 years of the Screening Visit) or current diagnosis or evidence of endocrine, hematological, immunological, renal, respiratory, neurologic, gastrointestinal, biliary, or genitourinary abnormalities or diseases that, per the investigator's judgement, may jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.

  11. Has a history of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed if they have received treatment and follow-up consistent with local standard of care.

  12. Participant history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Participants with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to screening.

  13. Has a history of human immunodeficiency virus disease.

  14. Participant has a history of gastric or small intestinal surgery (including gastric bypass surgery or banding but not including cholecystectomy or appendectomy) or has a disease that causes malabsorption.

    Laboratory, vital sign, and electrocardiogram (ECG) related

  15. Has a positive test result at screening for hepatitis B surface antigen (Ag), hepatitis C virus antibody.

  16. Has a screening estimated Glomerular Filtration Rate (eGFR) estimated with the Modification of Diet in Renal Disease (MDRD) equation of <45 ml/min/1.73 m^2.

  17. Has a screening result for alanine aminotransferase or aspartate aminotransferase (ALT or AST) of >2.0X upper limit of normal (ULN) or total bilirubin >1.5X ULN at the Screening Visit. Note: An isolated bilirubin >1.5X ULN is acceptable if bilirubin is fractionated, and direct bilirubin is within the laboratory normal range.

  18. Has a corrected QT interval to Fridericia's formula (QTcF) >450 milliseconds (msec) for males and >470 msec for females at screening.

  19. Has a mean value for triplicate seated systolic blood pressure >160 mmHg and/or diastolic blood pressure (BP) >95 mmHg measured after at least 5 minutes at rest at the Screening Visit.

    Note: If a participant's BP is exclusionary on the first triplicate assessment at the Screening Visit, they may have 1 repeat triplicate BP assessment at that visit after another rest of at least 10 minutes.

    Medication use and substance abuse related

  20. Has known history of or suspected abuse of alcohol or recreational drugs at screening.

  21. Has use of soft drugs (such as marijuana or any substances containing tetrahydrocannabinol (THC) or cannabidiol (CBD)) within 3 months prior to screening, or hard drugs (such as cocaine, illicit narcotics/opiates) within 6 months prior to screening.

  22. Has a positive drug screen at screening. Note: If benzodiazepines are detected on the drug screen, this is not exclusionary if they are prescribed a benzodiazepine for a therapeutic purpose (e.g. for insomnia) and confirmatory documentation is obtained from the prescribing physician.

  23. Is currently in violation of study requirements for prohibited and permissible concomitant medications (not already specified in other criteria) or is anticipated to violate these requirements during study participation.

  24. Has any use of prescription opiate medications within 14 days of screening or any anticipated/potential use of opiates during study participation.

  25. History of use of ergotamine medications on greater than/equal 10 days per month on a regular basis for greater than/equal 3 months prior to screening.

  26. History of non-narcotic analgesic intake on greater than/equal 15 days per month for greater than/equal 3 months prior to screening.

    Other

  27. Has known or suspected hypersensitivity to trial product(s) or related products.

  28. Has a history of multiple significant and/or any severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.

  29. Has any surgery scheduled for the duration of the trial.

  30. Had major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the Screening Visit; has a screening hemoglobin <11.0 g/dL (males) or <10.0 g/dL (females), or has a known hemoglobinopathy (e.g. sickle cell anemia, hemolytic anemia).

  31. Has previous participation in this trial. Participation is defined as signed informed consent.

  32. Has participated in any clinical trial of an approved or non-approved investigational biological medicinal product (e.g. antibody therapy) within 90 days of screening or has participated in any clinical trial of an approved or non-approved investigational small molecule medicinal product within 30 days or 5 half-lives (whichever is longer) of screening.

  33. Has any other disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.

  34. Is an employee or immediate family member (e.g., spouse, parent, child, sibling) of the Sponsor or study site.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Potroić

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Elismetrep (K-304) Dose Level 1

Participants received a single dose of elismetrep 2 mg

Administered orally

Eksperymentalny: Elismetrep (K-304) Dose Level 2

Participants received a single dose of elismetrep 5 mg

Administered orally

Eksperymentalny: Elismetrep (K-304) Dose Level 3

Participants received a single dose of elismetrep 10 mg

Administered orally

Eksperymentalny: Elismetrep (K-304) Dose Level 4

Participants received a single dose of elismetrep 20 mg

Administered orally

Komparator placebo: Placebo

Participants received a single dose of elismetrep-matched placebo

Administered orally

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Pain Freedom
Ramy czasowe: 2 hours post-dose

Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe)

2 hours post-dose

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Proportion of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)
Ramy czasowe: up to 7 days after administration of study therapy
up to 7 days after administration of study therapy
Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia or Photophobia)
Ramy czasowe: 2 hours post-dose

Assessed using the number of evaluable participants that reported the absence of their MBS

2 hours post-dose
Pain Relief
Ramy czasowe: 2 hours post-dose

Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1).

2 hours post-dose
Freedom From Photophobia
Ramy czasowe: 2 hours post-dose

Assessed by tabulating the number of participants that reported the absence of photophobia at 2 hours post-dose in the subset of participants that reported the presence of photophobia at baseline.

2 hours post-dose
Freedom From Phonophobia
Ramy czasowe: 2 hours post-dose

Assessed by tabulating the number of participants that reported the absence of phonophobia at 2 hours post-dose in the subset of participants that reported the presence of phonophobia at baseline.

2 hours post-dose
Freedom From Nausea
Ramy czasowe: 2 hours post-dose

Assessed by tabulating the number of participants that reported the absence of nausea at 2 hours post-dose in the subset of participants that reported the presence of nausea at baseline.

2 hours post-dose
The Probability of Requiring Rescue Medication
Ramy czasowe: 24 hours post-dose

Assessed using the number of participants that took rescue medication within 24 hours after administration of study therapy

24 hours post-dose
Sustained Pain Freedom
Ramy czasowe: From 2 to 24 hours

Assessed using the number of participants that did not experience any headache pain through the time period of interest

From 2 to 24 hours
Sustained Pain Relief
Ramy czasowe: From 2 to 24 hours

Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.

From 2 to 24 hours
Sustained Pain Freedom
Ramy czasowe: From 2 to 48 hours

Assessed using the number of participants that did not experience any headache pain through the time period of interest.

From 2 to 48 hours
Sustained Pain Relief
Ramy czasowe: From 2 to 48 hours

Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.

From 2 to 48 hours
Proportion of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)
Ramy czasowe: Up to 7 days after administration of study therapy

Serious adverse events were assessed in the Safety Analysis Set.

Up to 7 days after administration of study therapy

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

11 marca 2025

Zakończenie podstawowe (Rzeczywisty)

4 sierpnia 2025

Ukończenie studiów (Rzeczywisty)

4 sierpnia 2025

Daty rejestracji na studia

Pierwszy przesłany

21 lutego 2025

Pierwszy przesłany, który spełnia kryteria kontroli jakości

25 lutego 2025

Pierwszy wysłany (Rzeczywisty)

26 lutego 2025

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

20 października 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

25 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj